• Publications
  • Influence
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
TLDR
In patients who have an acute coronary syndrome with or without ST-segment elevation, treatment with ticagrelor as compared with clopidogrel significantly reduced the rate of death from vascular causes, myocardial infarction, or stroke without an increase in the rates of overall major bleeding but with an increase of non-procedure-related bleeding. Expand
Alogliptin after acute coronary syndrome in patients with type 2 diabetes.
TLDR
Among patients with type 2 diabetes who had had a recent acute coronary syndrome, the rates of major adverse cardiovascular events were not increased with the DPP-4 inhibitor alogliptin as compared with placebo. Expand
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
TLDR
In patients with type 2 diabetes and kidney disease, the risk of kidney failure and cardiovascular events was lower in the canagliflozin group than in the placebo group at a median follow-up of 2.62 years. Expand
Predictors of hospital mortality in the global registry of acute coronary events.
TLDR
Across the entire spectrum of ACS and in general clinical practice, this model provides excellent ability to assess the risk for death and can be used as a simple nomogram to estimate risk in individual patients. Expand
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.
TLDR
When added to statin therapy, ezetimibe resulted in incremental lowering of LDL cholesterol levels and improved cardiovascular outcomes, and lowering LDL cholesterol to levels below previous targets provided additional benefit. Expand
TIMI frame count: a quantitative method of assessing coronary artery flow.
TLDR
The CTFC is a simple, reproducible, objective and quantitative index of coronary flow that allows standardization of TIMI flow grades and facilitates comparisons of angiographic end points between trials. Expand
C-reactive protein levels and outcomes after statin therapy.
TLDR
Although atorvastatin was more likely than pravastatin to result in low levels of LDL cholesterol and CRP, meeting these targets was more important in determining the outcomes than was the specific choice of therapy. Expand
Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs.
TLDR
Impaired perfusion of the myocardium on coronary arteriography by use of the TMP grade is related to a higher risk of mortality after administration of thrombolytic drugs that is independent of flow in the epicardial artery. Expand
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.
TLDR
Among patients treated with clopidogrel for percutaneous coronary intervention, carriage of even 1 reduced-function CYP2C19 allele appears to be associated with a significantly increased risk of major adverse cardiovascular events, particularly stent thrombosis. Expand
Clopidogrel with or without omeprazole in coronary artery disease.
TLDR
The results do not rule out a clinically meaningful difference in cardiovascular events due to use of a PPI, but the two groups did not differ significantly in the rate of serious adverse events, though the risk of diarrhea was increased with omeprazole. Expand
...
1
2
3
4
5
...